The Role of Polymorphisms Near the IL28B Gene on Response to Peg-Interferon and Ribavirin in Thalassemic Patients With Hepatitis C

Bita Behnava, Heidar Sharafi, Maryam Keshvari, Ali Pouryasin, Leila Mehrnoush, Shima Salimi, Pegah Karimi Elizee, Mehran Ghazimoghaddam, Seyed Moayed Alavian, Bita Behnava, Heidar Sharafi, Maryam Keshvari, Ali Pouryasin, Leila Mehrnoush, Shima Salimi, Pegah Karimi Elizee, Mehran Ghazimoghaddam, Seyed Moayed Alavian

Abstract

Background: Hepatitis C Virus (HCV) is the major cause of liver failure in thalassemic patients. In these patients, iron overload and their comorbidities make difficulties during Pegylated-Interferon (PEG-IFN) and Ribavirin (RBV) therapy.

Objectives: We aimed to assess the impact of polymorphisms near the IL28B gene on virological response in HCV - infected thalassemic patients, who were treated with PEG-IFN and RBV.

Patients and methods: This cross - sectional study was conducted on 143 thalassemic patients with chronic hepatitis C, who were treated with a combination of PEG-IFN and RBV regimen. The rs12979860 and rs8099917 polymorphisms were assessed as the most common polymorphisms near the IL28B gene by the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method.

Results: The rate of sustained virological response (SVR) was significantly lower in thalassemic patients with HCV genotype-1 infection compared to patients with HCV genotype-3 infection. Among baseline predictors, rs12979860 and rs8099917 polymorphisms were found to be the only parameters associated with achievement of SVR in thalassemic patients with HCV genotype-1 infection however, there was no association between these polymorphisms and the rate of SVR in thalassemic patients with HCV genotype-3 infection.

Conclusions: In HCV genotype-1- infected thalassemic patients with rs12979860 CC genotype and without severe comorbidities, PEG-IFN and RBV combination therapy can be tried yet in those with rs12979860 CT/TT it may be reasonable to treat cases with new direct-acting antivirals.

Keywords: Genetic Polymorphism; Hepatitis C; Pegylated-Interferon; Ribavirin; Thalassemia.

Figures

Figure 1.. Rate of Rapid Virological Response,…
Figure 1.. Rate of Rapid Virological Response, Complete Early Virological Response, Sustained Virological Response, Relapse (Rel) and Non-response (NR) in Thalassemic Patients With Hepatitis C Virus in Relation to Hepatitis C Virus Genotypes.
Figure 2.. The Impact of rs12979860 Genotypes…
Figure 2.. The Impact of rs12979860 Genotypes on the Rate of Sustained Virological Response, Relapse and Non-response in Thalassemic Patients With Hepatitis C Virus Infection
A, The rate of SVR, relapse and non-response in thalassemic patients with HCV genotype-1 infection in relation to rs12979860 genotypes; B, The rate of SVR, relapse and non-response in thalassemic patients with HCV genotype-3 infection in relation to rs12979860 genotypes.

References

    1. Dehesa-Violante M, Nunez-Nateras R. Epidemiology of hepatitis virus B and C. Arch Med Res. 2007;38(6):606–11. doi: 10.1016/j.arcmed.2007.03.001.
    1. Mirmomen S, Alavian SM, Hajarizadeh B, Kafaee J, Yektaparast B, Zahedi MJ, et al. Epidemiology of hepatitis B, hepatitis C, and human immunodeficiency virus infecions in patients with beta-thalassemia in Iran: a multicenter study. Arch Iran Med. 2006;9(4):319–23.
    1. Alavian SM, Tabatabaei S, Lankarani K. Epidemiology of HCV Infection among Thalassemia Patients in Eastern Mediterranean Countries: a Quantitative Review of Literature. Iran Red Crescent Med J. 2010;12(4):365–76.
    1. Lai ME, Origa R, Danjou F, Leoni GB, Vacquer S, Anni F, et al. Natural history of hepatitis C in thalassemia major: a long-term prospective study. Eur J Haematol. 2013;90(6):501–7. doi: 10.1111/ejh.12086.
    1. Tabatabaei SV, Alavian SM, Keshvari M, Behnava B, Miri SM, Karimi Elizee P, et al. Low dose ribavirin for treatment of hepatitis C virus infected thalassemia major patients; new indications for combination therapy. Hepat Mon. 2012;12(6):372–81. doi: 10.5812/hepatmon.6592.
    1. Sood A, Sobti P, Midha V, Singla D, Kaur A, Kaushal S, et al. Efficacy and safety of pegylated IFN alfa 2b alone or in combination with ribavirin in thalassemia major with chronic hepatitis C. Indian J Gastroenterol. 2010;29(2):62–5. doi: 10.1007/s12664-010-0014-3.
    1. Taher AT, Musallam KM, Khalife M, Barada K. Hepatitis C antiviral response in thalassemia: what is the role of liver iron concentration? Ann Hematol. 2009;88(10):1033–4. doi: 10.1007/s00277-009-0713-y.
    1. Sharafi H, Alavian SM. IL28B polymorphism, Explanation for Different Responses to Therapy in Hepatitis C Patients. Hepat Mon. 2011;11(12):958–9. doi: 10.5812/kowsar.1735143X.794.
    1. Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology. 2010;138(4):1338–45. doi: 10.1053/j.gastro.2009.12.056.
    1. Ochi H, Maekawa T, Abe H, Hayashida Y, Nakano R, Imamura M, et al. IL-28B predicts response to chronic hepatitis C therapy--fine-mapping and replication study in Asian populations. J Gen Virol. 2011;92(Pt 5):1071–81. doi: 10.1099/vir.0.029124-0.
    1. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461(7262):399–401. doi: 10.1038/nature08309.
    1. Sharafi H, Pouryasin A, Alavian SM, Behnava B, Keshvari M, Mehrnoush L, et al. Development and Validation of a Simple, Rapid and Inexpensive PCR-RFLP Method for Genotyping of Common IL28B Polymorphisms: A Useful Pharmacogenetic Tool for Prediction of Hepatitis C Treatment Response. Hepat Mon. 2012;12(3):190–5. doi: 10.5812/hepatmon.849.
    1. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22(6):696–9.
    1. Keshvari M, Sharafi H, Hajarizadeh B, Alavian SM. Can we include genetic variants with high linkage disequilibrium into a multiple logistic model? Liver Int. 2014;34(6):964. doi: 10.1111/liv.12464.
    1. Sharafi H, Pouryasin A, Alavian SM, Behnava B, Keshvari M, Salimi S, et al. Distribution of IL28B Genotypes in Iranian Patients with Chronic Hepatitis C and Healthy Individuals. Hepat Mon. 2012;12(12):e32703. doi: 10.5812/hepatmon.8387.
    1. Sharafi H, Alavian SM, Behnava B, Pouryasin A, Keshvari M. The Impact of IFNL4 rs12979860 Polymorphism on Spontaneous Clearance of Hepatitis C; A Case-Control Study. Hepat Mon. 2014;14(10):e32703. doi: 10.5812/hepatmon.22649.
    1. Keshvari M, Pouryasin A, Behnava B, Sharafi H, Hajarizadeh B, Alavian SM. Letter: the rs12979860 and ss469415590 polymorphisms of IFNL4 gene are in strong linkage disequilibrium in Caucasian patients with chronic hepatitis C. Aliment Pharmacol Ther. 2014;39(3):343. doi: 10.1111/apt.12589.
    1. Samimi-Rad K, Shahbaz B. Hepatitis C virus genotypes among patients with thalassemia and inherited bleeding disorders in Markazi province, Iran. Haemophilia. 2007;13(2):156–63. doi: 10.1111/j.1365-2516.2006.01415.x.
    1. Alavian SM, Miri SM, Keshvari M, Elizee PK, Behnava B, Tabatabaei SV, et al. Distribution of hepatitis C virus genotype in Iranian multiply transfused patients with thalassemia. Transfusion. 2009;49(10):2195–9. doi: 10.1111/j.1537-2995.2009.02252.x.
    1. Samimi-Rad K, Nategh R, Malekzadeh R, Norder H, Magnius L. Molecular epidemiology of hepatitis C virus in Iran as reflected by phylogenetic analysis of the NS5B region. J Med Virol. 2004;74(2):246–52. doi: 10.1002/jmv.20170.
    1. Alavian SM, Tabatabaei SV. Treatment of chronic hepatitis C in polytransfused thalassaemic patients: a meta-analysis. J Viral Hepat. 2010;17(4):236–44. doi: 10.1111/j.1365-2893.2009.01170.x.
    1. Escudero A, Rodriguez F, Serra MA, Del Olmo JA, Montes F, Rodrigo JM. Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study. J Gastroenterol Hepatol. 2008;23(6):861–6. doi: 10.1111/j.1440-1746.2008.05397.x.
    1. Vafiadis I, Trilianos P, Vlachogiannakos J, Karagiorga M, Hatziliami A, Voskaridou E. Efficacy and safety of interferon-based therapy in the treatment of adult thalassemic patients with chronic hepatitis C: a 12 years audit. Annals of hepatology . Official j Mexican Hepat. 2013;12(4):532–8.
    1. Triantos C, Kourakli A, Kalafateli M, Giannakopoulou D, Koukias N, Thomopoulos K, et al. Hepatitis C in patients with beta-thalassemia major. A single-centre experience. Ann Hematol. 2013;92(6):739–46. doi: 10.1007/s00277-013-1692-6.
    1. Jimenez-Sousa MA, Fernandez-Rodriguez A, Guzman-Fulgencio M, Garcia-Alvarez M, Resino S. Meta-analysis: implications of interleukin-28B polymorphisms in spontaneous and treatment-related clearance for patients with hepatitis C. BMC Med. 2013;11:6. doi: 10.1186/1741-7015-11-6.
    1. Lin CY, Sheen IS, Chen JY, Huang CW, Huang CH, Jeng WJ, et al. Various predictors of sustained virologic response in different age groups of patients with genotype-1 chronic hepatitis C. J Clin Gastroenterol. 2013;47(9):794–9. doi: 10.1097/MCG.0b013e31829d2064.
    1. Haj-Sheykholeslami A, Keshvari M, Sharafi H, Pouryasin A, Hemmati K, Mohammadzadehparjikolaei F. Interferon-lambda polymorphisms and response to pegylated interferon in Iranian hepatitis C patients. World J Gastroenterol. 2015;21(29):8935–42. doi: 10.3748/wjg.v21.i29.8935.
    1. Di Marco V, Bronte F, Calvaruso V, Capra M, Borsellino Z, Maggio A, et al. IL28B polymorphisms influence stage of fibrosis and spontaneous or interferon-induced viral clearance in thalassemia patients with hepatitis C virus infection. Haematologica. 2012;97(5):679–86. doi: 10.3324/haematol.2011.050351.
    1. Rangnekar AS, Fontana RJ. IL-28B polymorphisms and the response to antiviral therapy in HCV genotype 2 and 3 varies by ethnicity: a meta-analysis. J Viral Hepat. 2013;20(6):377–84. doi: 10.1111/jvh.12039.
    1. Schinazi R, Halfon P, Marcellin P, Asselah T. HCV direct-acting antiviral agents: the best interferon-free combinations. Liver Int. 2014;34 Suppl 1:69–78. doi: 10.1111/liv.12423.
    1. Wendt A, Bourliere M. An update on the treatment of genotype-1 chronic hepatitis C infection: lessons from recent clinical trials. Ther Adv Infect Dis. 2013;1(6):191–208. doi: 10.1177/2049936113502647.
    1. Kim do Y, Ahn SH, Han KH. Emerging therapies for hepatitis C. Gut Liver. 2014;8(5):471–9. doi: 10.5009/gnl14083.
    1. European Association for Study of L. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol. 2015;63(1):199–236. doi: 10.1016/j.jhep.2015.03.025.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다